Antiplatelet therapies in diabetes

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus significantly increases cardiovascular morbidity and mortality.
• Diabetic patients exhibit advanced vascular pathology and a hypercoagulable state, characterized by platelet hyper-reactivity and altered coagulation factors.
• This thrombotic milieu contributes to the heightened risk of vascular events in this population.

Purpose of the Study:

• To review the role of antiplatelet agents in managing thrombotic risk in diabetes.
• To evaluate the efficacy of aspirin and P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) in primary and secondary vascular prevention in diabetic individuals.
• To provide a practical guide for healthcare professionals on optimizing antiplatelet therapy for improved vascular outcomes in diabetes.

Main Methods:

• Comprehensive literature review of current evidence on antiplatelet therapies in diabetes.
• Analysis of studies investigating aspirin for primary and secondary prevention.
• Examination of data on P2Y12 inhibitors for short- and long-term secondary prevention.
• Inclusion of data on special populations such as aspirin-intolerant individuals, and those with peripheral or cerebrovascular disease.

Main Results:

• Aspirin is established for primary and secondary vascular prevention in diabetes.
• P2Y12 inhibitors demonstrate efficacy in both short- and long-term secondary prevention settings.
• Evidence supports the use of antiplatelet agents in specific diabetic subgroups with vascular disease.

Conclusions:

• Antiplatelet therapy is crucial for mitigating thrombotic risk in patients with diabetes.
• Tailored antiplatelet strategies, considering individual patient factors and specific vascular conditions, are essential for optimizing vascular outcomes.
• This review offers a pragmatic framework for clinicians managing antiplatelet treatment in diabetic populations to reduce cardiovascular complications.